Found 0 matching trials
Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food PHASE4 This single-arm, open-label, multi-center study enrolled 65 patients from a...
Show More Location
Children's Hospital and Research Center
Learn More & Join Trial
Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome PHASE2 This phase II trial studies how well deferasirox works in treating patients...
Show More Location
Fred Hutch/University of Washington Cancer Consortium
Learn More & Join Trial
Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both PHASE1 Subjects with thalassemia major require regular transfusion therapy to sust...
Show More Location
Weill Cornell Medical Center
Learn More & Join Trial
Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration) PHASE4 To allow patients treated with deferasirox in the core study to continue ir...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet PHASE2 Study to evaluate patient preference of deferasirox film-coated tablet (FCT...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload PHASE3 This is an open-label, non-randomized, multi-center trial designed to provi...
Show More Location
Arkansas Children's Hospital, UAMS College of Medicine
Learn More & Join Trial
Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload PHASE4 The purpose of this study is to investigate the effects of iron chelation u...
Show More Location
Novartis Investigative Site
Learn More & Join Trial
Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS) PHASE2 Myelodysplastic syndromes are common blood disorders that can affect as man...
Show More Location
Odette Cancer Centre, Sunnybrook Health Sciences Centre
Learn More & Join Trial
Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions PHASE3 The purpose of this study is to deterimine if the new orally active iron ch...
Show More Location
Children's Hospital of Los Angeles
Learn More & Join Trial
Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation PHASE2 This study is a multicenter, open-label, two-period crossover design that e...
Show More Location
Weill Cornell Medicine, New York-Presbyterian Hospital
Learn More & Join Trial